Communications Biology (Sep 2022)
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
- Claudia Maria Trombetta,
- Giulia Piccini,
- Giulio Pierleoni,
- Margherita Leonardi,
- Francesca Dapporto,
- Serena Marchi,
- Emanuele Andreano,
- Ida Paciello,
- Linda Benincasa,
- Piero Lovreglio,
- Nicola Buonvino,
- Nicola Decaro,
- Angela Stufano,
- Eleonora Lorusso,
- Emilio Bombardieri,
- Antonella Ruello,
- Simonetta Viviani,
- Rino Rappuoli,
- Eleonora Molesti,
- Alessandro Manenti,
- Emanuele Montomoli
Affiliations
- Claudia Maria Trombetta
- Department of Molecular and Developmental Medicine, University of Siena
- Giulia Piccini
- VisMederi srl
- Giulio Pierleoni
- VisMederi srl
- Margherita Leonardi
- VisMederi Research srl
- Francesca Dapporto
- VisMederi Research srl
- Serena Marchi
- Department of Molecular and Developmental Medicine, University of Siena
- Emanuele Andreano
- Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
- Ida Paciello
- Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
- Linda Benincasa
- VisMederi Research srl
- Piero Lovreglio
- Interdisciplinary Department of Medicine, Section of Occupational Medicine, University of Bari
- Nicola Buonvino
- U.O.C. Penitentiary Medicine—Department of Territorial Care, Bari Local Health Authority
- Nicola Decaro
- Department of Veterinary Medicine, University of Bari
- Angela Stufano
- Interdisciplinary Department of Medicine, Section of Occupational Medicine, University of Bari
- Eleonora Lorusso
- Department of Veterinary Medicine, University of Bari
- Emilio Bombardieri
- Humanitas Gavazzeni
- Antonella Ruello
- Humanitas Gavazzeni
- Simonetta Viviani
- Department of Molecular and Developmental Medicine, University of Siena
- Rino Rappuoli
- Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
- Eleonora Molesti
- VisMederi Research srl
- Alessandro Manenti
- VisMederi srl
- Emanuele Montomoli
- Department of Molecular and Developmental Medicine, University of Siena
- DOI
- https://doi.org/10.1038/s42003-022-03849-0
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 7
Abstract
Antibodies elicited by a triple homologous or heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1.
